Full-Time

Director – CMC Writing

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

No salary listed

Senior, Expert

No H1B Sponsorship

Norwood, MA, USA

In Person

70% in-office structure required for this position.

US Citizenship Required

Category
Technical Writing
Content & Writing
Requirements
  • BS or MS with 15 to 20+ years of relevant industry experience, or PhD with 10 to 15+ years of relevant experience in CMC technical development (e.g. process or analytical development) and technical writing for regulatory submissions (e.g., INDs, BLAs).
Responsibilities
  • Serve as a primary CMC technical writing consultant, reviewer, and editor for key strategic documents, working with subject matter experts (SMEs) to ensure clarity, accuracy, and regulatory alignment prior to submission.
  • Implement metrics to assess document quality and effectiveness.
  • Introduce best practices for authoring and review of CMC documents to drive continuous improvement against document quality metrics, efficiency targets, and phase-appropriate expectations.
  • Champion the adoption and integration of digital solutions, including artificial intelligence (AI), to enhance efficiency, readability, and document consistency across the product portfolio.
  • Manage the internal communication and lifecycle of key CMC strategic positions, ensuring stakeholders have access the current and historical state of information and decisions.
  • Create and deliver technical writing curricula for authors and reviewers as part of ongoing SME skill development.
  • Additional duties as may be assigned from time to time.
Desired Qualifications
  • Extensive experience authoring and reviewing CMC sections for regulatory filings and deep understanding of the interpretation and application of regulatory guidance (e.g. ICH).
  • Demonstrated ability to translate complex technical data and strategies into clear and compelling narrative aligned with regulator expectations and guidance.
  • Significant prior experience both as a technical subject matter expert and as a dedicated CMC technical writer or manager of a CMC technical writers.
  • Exceptional written and verbal communication skills, adept at conveying complex technical concepts, and proactively identifying risk and addressing challenges.
  • Proven matrix leadership capabilities to effectively navigate complex, cross-functional environments.
  • A high standard and well-articulated vision of what excellence looks like in CMC technical writing for regulatory submissions and a strong passion to educate and coach authors to reach this level.
  • Experience in development of technical writing training curricula.
  • Passion for innovation, particularly leveraging AI and emerging technologies, to transform documentation processes.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for biological functions. Their products work by delivering mRNA into the body, which instructs cells to create specific proteins that can help prevent or treat diseases. This approach is different from traditional medicines, as it allows for a more direct and potentially faster way to develop treatments. Moderna's goal is to create a new category of medicines that can significantly enhance patient care and improve health outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's RSV vaccine received regulatory approval in Australia, expanding its infectious disease portfolio.
  • The collaboration with Merck on personalized cancer vaccines shows promising early trial results.
  • Moderna's mRNA technology is gaining traction in personalized medicine and infectious disease prevention.

What critics are saying

  • Moderna faces reputational damage from a bribery scandal related to COVID-19 vaccine trials.
  • HHS funding cancellation for bird flu vaccine development may impact Moderna's revenue streams.
  • Regulatory delays could slow down Moderna's product pipeline and affect its competitive edge.

What makes Moderna unique

  • Moderna is pioneering mRNA technology as a new class of medicines.
  • The company collaborates with IBM Quantum to enhance mRNA drug design using quantum computing.
  • Moderna's AI-driven research partnership with Benchling highlights its innovative approach to drug discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

3%
Meet the People
Jun 2nd, 2025
Social Media Campaign of the Year - Healthcare Marketing Impact Awards

Meet The People, LLC is delighted to share that Coegi's SpikevaxPartner campaign with Moderna has been recognized as a Social Media Campaign of the Year in the 2024 Healthcare Marketing Impact Awards by Modern Healthcare and Ad Age!

The Washington Post
May 28th, 2025
HHS cancels funding for Moderna to develop vaccines to combat bird flu

HHS cancels funding for Moderna to develop vaccines to combat bird flu.

FermionIQ
May 20th, 2025
Quantum-centric workflows for predicting RNA secondary structure

In a recent collaboration with Moderna and IBM Quantum, Fermioniq developed two quantum-centric optimization algorithms to predict mRNA secondary structure - a key challenge in computational biology with direct implications for mRNA-based drug design.

Things of Business
May 7th, 2025
Benchling and Moderna Collaborate on AI-Driven Research

SAN FRANCISCO and BOSTON, May 7, 2025 - Benchling, the R&D platform powering the biotech industry, today announced an expanded collaboration with Moderna.

Parriva
May 6th, 2025
Flesh-Eating Bacteria Surge in California: What You Need to Know

Moderna is reportedly working on a candidate vaccine using similar mRNA technology to its COVID-19 formula, but experts express concern about regulatory delays.